GLUE
Monte Rosa Therapeutics Inc
10.20$
+3.0%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -87.8% | +341.3% | +96.3% | +558.1% | +40.0% | -72.7% | -45.0% | -78.2% | +51.4% | +113.0% | – | |
| – | – | – | – | – | +70.4% | +24.6% | +39.0% | +39.9% | +91.6% | +18.8% | +4.1% | -57.1% | +20.9% | +31.8% | +0.7% | +2.8% | +8.6% | +2.1% | -2.0% | – | – | -1.4% | -0.3% | -2.8% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +249.8% | +558.1% | +40.0% | -72.7% | -45.0% | -78.2% | -21.6% | +311.2% | – | |
| – | +27.3% | +12.7% | +80.2% | -6.0% | +57.8% | +3.3% | +19.9% | -1.2% | +16.9% | +1.9% | +16.5% | +7.6% | +8.7% | -2.6% | -4.1% | -7.4% | +3.4% | +6.2% | +40.7% | -17.2% | -4.8% | +19.7% | +14.5% | +5.0% | +8.8% | – | |
| – | +13.2% | +68.9% | +126.8% | +7.6% | +56.3% | +36.3% | +10.6% | +21.5% | -1.4% | +11.5% | +8.6% | -1.5% | +8.5% | +6.3% | -10.8% | +16.3% | +3.3% | -12.4% | +8.0% | -0.8% | -7.0% | +12.0% | +16.0% | -3.3% | -0.4% | – | |
| – | +25.7% | +18.3% | +86.9% | -3.6% | +57.5% | +9.6% | +17.7% | +3.9% | +12.1% | +4.2% | +14.6% | +5.4% | +8.6% | -0.7% | -5.7% | -2.1% | +3.4% | +1.3% | +33.3% | -14.2% | -5.2% | +18.1% | +14.8% | -0.5% | +11.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +238.6% | -135.3% | – | – | – | – | – | |
| – | -66.7% | +100.0% | +350.0% | -33.3% | +133.3% | -7.1% | +0.0% | +1,046.2% | +321.5% | +58.8% | +99.6% | -53.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +205.8% | -123.3% | – | – | – | – | – | |
| – | -1,166.7% | – | -76.7% | -570.0% | – | -317.4% | – | – | – | – | – | – | – | -10.5% | -112.9% | – | +203.6% | -71.8% | +2,947.9% | -62.0% | +45.9% | -365.0% | – | -11.9% | +300.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +248.9% | -126.2% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +181.7% | -118.0% | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.